(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 May 2019 (09.05.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/090364 A1

(51) International Patent Classification:
A61K 31/55 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2018/059510

(22) International Filing Date:
06 November 2018 (06.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/582,308 06 November 2017 (06.11.2017) US
62/582,937 07 November 2017 (07.11.2017) US
62/665,450 01 May 2018 (01.05.2018) US

(71) Applicants: **JUNO THERAPEUTICS, INC.** [US/US]; 400 Dexter Avenue N, Suite 1200, Seattle, Washington 98109 (US). **FRED HUTCHINSON CANCER RESEARCH CENTER** [US/US]; 1100 Fairview Avenue North, Seattle, Washington 98109-1024 (US).

(72) Inventors: **GREEN, Damian J.**; 1100 Fairview Avenue North, Seattle, Washington 98109-1024 (US). **RIDDELL, Stanley R.**; 1100 Fairview Avenue North, Seattle, Washington 98109-1024 (US). **WORKS, Melissa**; 400 Dexter Avenue N., Suite 1200, Seattle, Washington 98109 (US).

(74) Agent: **POTTER, Karen** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: COMBINATION OF A CELL THERAPY AND A GAMMA SECRETASE INHIBITOR




FIG. 1

(57) Abstract: Provided herein are combination therapies involving administration of an immunotherapy involving a cell therapy, such as a T cell therapy, and an inhibitor of gamma secretase. Also provided are methods for engineering, preparing, and producing the cells, compositions containing the cells and/or gamma secretase inhibitor, and kits and devices containing and for using, producing and administering the cells and/or gamma secretase inhibitor, such as in accord with the provided combination therapy methods.

[Continued on next page]

WO 2019/090364 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*